No Data
Madrigal Pharmaceuticals: Stable Performance Amidst Uncertain Future and Conservative Valuation
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Update: Madrigal Pharmaceuticals Shares Decline After Posting Preliminary Q4 Rezdiffra Net Sales of Up to $103 Million
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $427
Madrigal Shares Fall 16% On Preliminary 2024 Earnings
Express News | Madrigal Pharmaceuticals Shares Are Trading Lower After the Company Reported Preliminary Q4 and FY24 Financial Results
Market Maverick7 : what do you see from ATHA?
George Soros II Market Maverick7 : As he mentioned, unusual volumes
Market Maverick7 George Soros II : good news?
Stock_Drift OP Market Maverick7 : I see it broke the .54 resistance.
yesyesyes : $Trio Petroleum (TPET.US)$
View more comments...